Literature DB >> 12488241

Adipose tissue sensitization to insulin induced by troglitazone and MEDICA 16 in obese Zucker rats in vivo.

Bella Kalderon1, Nina Mayorek, Limor Ben-Yaacov, Jacob Bar-Tana.   

Abstract

The putative role played by insulin sensitizers in modulating adipose tissue lipolysis in the fasting state was evaluated in obese conscious Zucker rats treated with troglitazone or beta,beta'-tetramethylhexadecanedioic acid (MEDICA 16) and compared with nontreated lean and obese animals. The rates of appearance (R(a)) of glycerol and free fatty acid (FFA), primary intra-adipose reesterification, and secondary reuptake of plasma FFA in adipose fat were measured using constant infusion of stable isotope-labeled [(2)H(5)]glycerol, [2,2-(2)H(2)]palmitate, and radioactive [(3)H]palmitate. The overall lipolytic flux (R(a) glycerol) was increased 1.7- and 1.4-fold in obese animals treated with troglitazone or MEDICA 16, respectively, resulting in increased FFA export (R(a) FFA) in the troglitazone-treated rats. Primary intra-adipose reesterification of lipolysis-derived fatty acids was enhanced twofold by insulin sensitizers, whereas reesterification of plasma fatty acids was unaffected by either treatment. Despite the unchanged R(a) FFA in MEDICA 16 or the increased R(a) FFA induced by troglitazone, very low density lipoprotein production rates were robustly curtailed. Total adipose tissue reesterification, used as an estimate of glucose conversion to glyceride-glycerol, was increased 1.9-fold by treatment with the insulin sensitizers. Our results indicate that, in the fasting state, insulin sensitizers induce, in vivo, a significant activation rather than suppression of adipose tissue lipolysis together with stimulation of glucose conversion to glyceride-glycerol.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12488241     DOI: 10.1152/ajpendo.00368.2002

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  7 in total

1.  Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment.

Authors:  Faidon Magkos; Christos S Mantzoros
Journal:  Metabolism       Date:  2010-10-20       Impact factor: 8.694

2.  PPARgamma agonism increases rat adipose tissue lipolysis, expression of glyceride lipases, and the response of lipolysis to hormonal control.

Authors:  W T Festuccia; M Laplante; M Berthiaume; Y Gélinas; Y Deshaies
Journal:  Diabetologia       Date:  2006-08-14       Impact factor: 10.122

3.  PPARgamma regulates adipose triglyceride lipase in adipocytes in vitro and in vivo.

Authors:  Erin E Kershaw; Michael Schupp; Hong-Ping Guan; Noah P Gardner; Mitchell A Lazar; Jeffrey S Flier
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-09-11       Impact factor: 4.310

4.  Regulation of Insulin Receptor Pathway and Glucose Metabolism by CD36 Signaling.

Authors:  Dmitri Samovski; Pallavi Dhule; Terri Pietka; Miriam Jacome-Sosa; Eric Penrose; Ni-Huiping Son; Charles Robb Flynn; Kooresh I Shoghi; Krzysztof L Hyrc; Ira J Goldberg; Eric R Gamazon; Nada A Abumrad
Journal:  Diabetes       Date:  2018-05-10       Impact factor: 9.461

5.  Activin receptor-like kinase 7 suppresses lipolysis to accumulate fat in obesity through downregulation of peroxisome proliferator-activated receptor γ and C/EBPα.

Authors:  Satomi Yogosawa; Shin Mizutani; Yoshihiro Ogawa; Tetsuro Izumi
Journal:  Diabetes       Date:  2012-08-28       Impact factor: 9.461

6.  Depot-Specific Changes in Fat Metabolism with Aging in a Type 2 Diabetic Animal Model.

Authors:  Se Eun Park; Cheol-Young Park; Jung Mook Choi; Eugene Chang; Eun-Jung Rhee; Won-Young Lee; Ki Won Oh; Sung Woo Park; Eun Seok Kang; Hyun Chul Lee; Bong Soo Cha
Journal:  PLoS One       Date:  2016-02-19       Impact factor: 3.240

Review 7.  Targeting nuclear receptors with marine natural products.

Authors:  Chunyan Yang; Qianrong Li; Yong Li
Journal:  Mar Drugs       Date:  2014-01-27       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.